Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atranorin shows significant antinociceptive and antiinflammatory activities, it has a relevant redox-active action, acting as a pro-oxidant or antioxidant agent depending on the radical, also, it will exert cytoprotective effects on cells under oxidative stress induced by H(2)O(2).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 108.00 | |
5 mg | In stock | $ 266.00 | |
10 mg | In stock | $ 393.00 | |
25 mg | In stock | $ 659.00 | |
50 mg | In stock | $ 939.00 | |
100 mg | In stock | $ 1,270.00 |
Description | Atranorin shows significant antinociceptive and antiinflammatory activities, it has a relevant redox-active action, acting as a pro-oxidant or antioxidant agent depending on the radical, also, it will exert cytoprotective effects on cells under oxidative stress induced by H(2)O(2). |
In vitro | Three lichen secondary metabolites Atranorin (1), evernic acid (2), and usnic acid (3), were evaluated for their in vitro clastogenic and antiproliferative effects on human lymphocytes using the cytochalasin-B blocked micronucleus (CBMN) assay at concentrations of 2 microg/mL, 4 microg/mL and 6 microg/mL of final culture solution. Atranorin at concentrations of 2 microg/mL and 4 microg/mL decreasing the frequency of MN only for 11.1% and 1.8%, while in concentration of 6 microg/mL increases the frequency of MN for 9.6 %[1] |
Source |
Molecular Weight | 374.34 |
Formula | C19H18O8 |
CAS No. | 479-20-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Atranorin 479-20-9 GPCR/G Protein Immunology/Inflammation MAPK Metabolism NO Synthase Endogenous Metabolite Ras AP-1 metabolite secondary Wnt inhibit β-catenin Lichen STAT anti-tumor Inhibitor inhibitor